Montara Therapeutics
Founded 2022 · CIK 0002008775 · Biotech · Private
RNA-targeted small molecule therapeutics for neuromuscular and rare genetic diseases
montaratx.com →- Grants
- —
- No SBIR or STTR on record
- Sector median: 1
- Raised
- $28M
- 2 Form D · Mar 2025
- 19 months since last filing
- Contracts
- —
- No federal contracts on record
- Patents
- 13
- 0 granted · 13 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓202320242025
| Date | Event | Source | Amount |
|---|---|---|---|
| Private capital raised | Form D · SEC | $8,000,011 | |
| Private capital raised | Form D · SEC | $19,999,995 |
Form D · SEC
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 2363 | ACRIGEN BIOSCIENCES, INC. | — | $775K |
| 2364 | MARCH BIOSCIENCES INC | — | $22M |
| 2365 | Biodesy LLC | — | $350K |
| 2366 | Montara Therapeutics | — | $28M |
| 2367 | VST BIO Corp | — | $29M |
| 2368 | Propagenix Inc | — | $2.3M |
| 2369 | Merida Biosciences | — | — |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Founders & Team
- Randall ChinExecutive Officer
- Nicholas HertzDirector · Executive Officer · Promoter
- Zachary HillExecutive Officer
- Dirk LangdorfDirector
- Max LebovitzExecutive Officer
- Rishi RakhitExecutive Officer
- Seth StrattonDirector
- Troy WilsonDirector
Patents
- Central Nervous System-selective Activity Of Lxr Agonistsapplication
- Central Nervous System-selective Activity Of LRRK2 Inhibitorsapplication
- Central Nervous System-selective Activity Of Everolimusapplication
- Peripheral Blockers For Central Nervous System-selective Drug Activityapplication
- Central Nervous System-selective Activity Of Lxr Agonistsapplication
- Central Nervous System-selective Activity Of LRRK2 Inhibitorsapplication
- Central Nervous System-selective Activity Of Everolimusapplication
- Peripheral Blockers For Central Nervous System-selective Drug Activityapplication
- Central Nervous System-selective Activity Of LRRK2 Inhibitorsapplication
- Central Nervous System-selective Activity Of Everolimusapplication
- Central Nervous System-selective Activity Of Tacrolimusapplication
- Peripheral Blockers For Central Nervous System-selective Drug Activityapplication
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.